CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference

Stock News

03/24

CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million. The increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/1152835973"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1152835973\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1152835973?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-24 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1152835973","market":"other","top_or_hot":-1,"title":"CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference","media":"Stock News","content":"<p>CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCSTONE PHARMA-B Shares Climb Over 4% on Triple Pipeline Recognition at Prestigious Cancer Conference\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time smaller\">2026-03-24 10:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"","article_id":"1152835973","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1152835973","pubTimestamp":1774319068,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million. The increase follows recent news that the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","BK4585":"ETF&股票定投概念","VXUS":"国际股票ETF-Vanguard","BK1574":"生物医药B类股","02616":"基石药业-B","BK4588":"碎股"},"translate_title":"基石药业-B股价因三重管道在著名癌症会议上获得认可而上涨超过4%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VXUS":1,"02616":1},"content_text":"CStone Pharmaceuticals-B (02616) rose more than 4%. At the time of writing, the stock was up 3.05%, trading at HK$6.41 with a turnover of HK$18.1843 million.\nThe increase follows recent news that the company announced preclinical research results from three of its self-developed drug pipelines have been successfully selected for the poster presentation session at the 2026 Annual Meeting of the American Association for Cancer Research (AACR). This conference is one of the most influential academic gatherings in the global field of cancer research. The 2026 annual meeting is scheduled to be held from April 17 to April 22, 2026, at the San Diego Convention Center in California, USA. Related research abstracts will be published on April 3, 2026, in the AACR's official journal, *Cancer Research*.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}